Share This Author
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
This study shows that PARP inhibitors trap the PARP1 and PARP2 enzymes at damaged DNA, providing a new mechanistic foundation for the rational application ofPARP inhibitors in cancer therapy.
Topoisomerase I inhibitors: camptothecins and beyond
- Y. Pommier
- Chemistry, BiologyNature Reviews. Cancer
- 1 October 2006
The mechanisms and molecular determinants of tumour response to TOP1 inhibitor are reviewed, and rational combinations of TOP1 inhibitors with other drugs are considered based on current knowledge of repair and checkpoint pathways that are associated with TOP1-mediated DNA damage.
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
A gene expression database for the molecular pharmacology of cancer
Gene-drug relationships for the clinical agents 5-fluorouracil and L-asparaginase exemplify how variations in the transcript levels of particular genes relate to mechanisms of drug sensitivity and resistance.
γH2AX and cancer
Using γH2AX detection to determine the extent of DSB induction may help to detect precancerous cells, to stage cancers, to monitor the effectiveness of cancer therapies and to develop novel anticancer drugs.
CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.
A CellMiner web application is introduced designed to improve the use of the extensive NCI-60 cell line database for discovery by creating web-based processes that are rapid, flexible, and readily applied by users without bioinformatics expertise.
Integrase inhibitors to treat HIV/Aids
This review focuses on the molecular basis and rationale for developing integrase inhibitors, as well as the main classes of lead compounds and interfacial inhibitors of protein–nucleic-acid interactions that might apply to the clinically used strand-transfer inhibitors.
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
- Y. Pommier, Yilun Sun, Shar-yin N. Huang, J. Nitiss
- BiologyNature reviews. Molecular cell biology
- 1 November 2016
The roles of topoisomerases in mediating chromatin dynamics, transcription, replication, DNA damage repair and genomic stability are reviewed, and how deregulation of top Loisomerases can cause neurodegenerative diseases, immune disorders and cancer are discussed.
Drugging topoisomerases: lessons and challenges.
- Y. Pommier
- BiologyACS Chemical Biology
- 18 January 2013
This review discusses how topoisomerase inhibitors kill cells by trapping topoisomersases on DNA rather than by classical enzymatic inhibition, and extends to a novel mechanism of action of PARP inhibitors and could be applied to the targeting of transcription factors.
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- J. Murai, Shar-yin N. Huang, Y. Pommier
- Biology, ChemistryMolecular Cancer Therapeutics
- 19 December 2013
BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes and is also approximately 100-fold more cytotoxic than olaparib and rucaparIB in combination with the DNA alkylating agents methyl methane sulfonate and temozolomide.